Drugs / iNKT cells

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07713290 Apr 2025 → Nov 2026 expected hepatocellular carcinoma Beijing Gene Key Life Technology Co., Ltd Active not recruiting No outcome recorded
Phase 1 NCT03175679 Apr 2017 → Dec 2018 hepatocellular carcinoma Beijing YouAn Hospital Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT03551795 Jan 2018 → Dec 2021 cancer Xiaoyan Zhang Completed No outcome recorded
Phase 1/2 NCT03093688 Mar 2017 → Dec 2030 expected gastric cancer, hepatocellular carcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 Shanghai Public Health Clinical Center Recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT07209813 Oct 2025 → Oct 2026 expected hepatocellular carcinoma Beijing Gene Key Life Technology Co., Ltd Not yet recruiting No outcome recorded
Phase 2 NCT05962450 Oct 2023 → Aug 2025 hepatocellular carcinoma Beijing YouAn Hospital Unknown No outcome recorded
Phase 2 NCT04011033 Mar 2018 → Mar 2020 hepatocellular carcinoma Beijing YouAn Hospital Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as iNKT cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT03093688
4

NCT03551795

NCT05962450

NCT03175679

NCT04011033

Known as GKL-006 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07209813
1

NCT07713290

Known as Invariant Natural killer T Invariant Natural killer T (iNKT) cells are a unique subset of lymphocytes” NCT03093688
Action Deplete “Human iNKT cells can directly lysis tumor cells by a perforin-dependent mechanism” NCT03093688
Modality Cell therapy “immunotherapy strategy of infusion of iNKT cells” NCT03551795
Route Intravenous “through intravenous infusion” NCT03175679